#United States #Prolacta Bioscience #Duarte #NICU #preemies

Prolacta Bioscience Celebrates NICU Awareness Month Milestone

September marks NICU Awareness Month, a time dedicated to recognizing the significant care offered to premature and critically ill newborns. Prolacta Bioscience®, a pioneering company dedicated to developing nutritional products solely derived from human milk, is proud to announce a major achievement: the successful support of over 125,000 preterm infants globally with its innovative 100% human milk-based nutrition.

This remarkable milestone reflects the company's relentless commitment to advancing neonatal care, particularly within neonatal intensive care units (NICUs). Since the introduction of the world’s first and only 100% human milk-based fortifier, Prolact+ H2MF®, in 2006, Prolacta has set a new standard for neonatal nutrition. Unlike traditional cow milk-based products, Prolacta's formulations are made exclusively from donor breast milk, ensuring that fragile infants receive the best possible start in life while minimizing the risk of complications often associated with prematurity, such as necrotizing enterocolitis (NEC).

Scott Elster, CEO of Prolacta, expressed pride in reaching this important landmark: "Reaching more than 125,000 fragile babies is more than a statistic; it represents thousands of families who have seen the difference breast milk-based nutrition can make during the most critical time in their babies' lives. This milestone reflects the dedication of NICU care teams who understand the pivotal role breast milk-based nutrition plays in the survival and long-term health of the smallest premature infants."

Studies have shown that infants receiving an Exclusive Human Milk Diet (EHMD) with Prolacta's products experience increased survival rates and a reduced incidence of typical complications associated with prematurity. Compared to infants on cow milk-based diets, those on Prolacta’s breast milk-based formulations not only survive but thrive, setting the foundation for healthier development as they grow. Furthermore, research indicates that babies fed with Prolacta's nutritional products often reach important developmental milestones sooner and with fewer challenges than their peers on traditional diets.

As NICU Awareness Month is recognized every September, it serves to highlight the indispensable role that NICUs play in caring for the most vulnerable newborns. In the U.S. alone, approximately 36,000 babies are born each year weighing less than 2.75 lbs, facing increased risks of severe complications. Many medical professionals and advocates celebrate the role that advances in neonatal nutrition have in improving these infants’ chances not just to survive but to grow up healthy and thrive.

Prolacta's groundbreaking products have undergone extensive evaluation in over 30 peer-reviewed clinical studies, supporting the efficacy and safety of human milk-based nutrition. The company's dedication not only lies in creating innovative solutions but also in maintaining rigorous quality control measures to ensure the utmost safety for infants. Prolacta operates the world’s first pharmaceutical-grade human milk processing facilities which adhere to strict safety standards, ensuring that every drop of milk retains its nutritional value and bioactivity crucial for sustaining infant health.

To learn more about Prolacta Bioscience and how their nutrition products transform lives, visit parents.prolacta.com. Major advancements in neonatal care are being made, and with continued awareness and support, the future of vulnerable children can indeed be brighter. Together, we can ensure that every fragile life has the chance to thrive.